Tools for CXCR7 Characterization, Screening, and Profiling
CXCR7 (or ACKR3) is an atypical chemokine receptor (ACKR) that binds with high affinity to the inflammatory and homing chemokines CXCL11/ITAC and CXCL12/SDF-1. CXCR7 is expressed in the bladder, spleen, heart, skeletal muscle, peripheral nervous system and placenta. Similar to other ACKRs, CXCR7 does not activate Gα-mediated signaling. Evidence does suggest that CXCR7/SDF-1α binding stimulates β-arrestin-mediated recruitment and signaling, and that CXCR7 functions beyond acting as a simple decoy to regulate CXCR4/SDF-1α binding.
Read our Scientific Insight: Unraveling CXCR7 Signaling & Therapeutic Potentials
CXCR7 Cells, Membranes & β-arrestin Reagents
Multispan offers a portfolio of high-quality CXCR7 cell line and β-arrestin recruitment assay reagents and kits. Our β-arrestin sensor technology enables CXCR7 “tag-less” monitoring of β-arrestin recruitment.
Multispan cell lines are clonally-derived with rigorous quality control that ensures 99% of the stable cell lines pass 2-month stability. Additionally, all cell lines, including our CXCR7 stable cell line, are fully validated using MultiScreenTM high throughput signaling assays in 384-well format.
| Receptor | Species | Parental | Stable Cell Line | Division-Arrested Cells | Membranes |
|---|---|---|---|---|---|
|
CXCR7 |
human |
HEK293T |
DC1150 |
MC1150 |
| Reagents | Catalog Number |
|---|---|
|
MSBAK01 |
|
|
MSBAKBM01 |
|
|
MSBAKHSV01 |
Don’t see the CXCR7 tool you need? Check out Multispan’s complete service offering including custom cell line generation, high throughput screening & profiling, and cell scale up & banking.
MultiScreen β-Arrestin Recruitment Assays - The Next Generation
MultiScreen β-arrestin assays use translocation of β-arrestin as the assay readout; however, it is β-arrestin and a membrane ‘sensor’ that are tagged rather than the GPCR of interest. Upon recruitment, tagged arrestin comes within proximity of a membrane sensor which in turns results in a functional luciferase enzyme.
This scheme overcomes receptor tagging required by other β-Arrestin assays which can be deleterious, induce receptor conformational changes, lead to steric hinderance, or modify receptor pharmacology – all of which impact the identification and optimization of highly qualified drug candidates.
